BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/13/2025 2:41:30 AM | Browse: 293 | Download: 1150
 |
Received |
|
2024-08-28 06:51 |
|
Peer-Review Started |
|
2024-08-28 09:26 |
|
First Decision by Editorial Office Director |
|
2024-12-29 02:02 |
|
Return for Revision |
|
2024-12-31 11:35 |
|
Revised |
|
2025-01-06 11:55 |
|
Publication Fee Transferred |
|
2025-01-10 09:07 |
|
Second Decision by Editor |
|
2025-01-18 02:46 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-01-18 08:59 |
|
Articles in Press |
|
2025-01-18 08:59 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-05 09:25 |
|
Publish the Manuscript Online |
|
2025-02-13 02:41 |
| ISSN |
1948-5190 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Masashi Ohno, Atsushi Nishida, Akinori Otsuki, Yoshihiro Yokota, Takayuki Imai, Shigeki Bamba and Osamu Inatomi |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan |
No. 21K15947 |
| Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan |
No. 23K07435 |
|
| Corresponding Author |
Masashi Ohno, Assistant Professor, MD, PhD, Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Shiga, Japan. ohno116@belle.shiga-med.ac.jp |
| Key Words |
Crohn’s disease; Leucine-rich alpha-2 glycoprotein; Endoscopic activity; Ileum; Small intestine; Balloon-assisted enteroscopy |
| Core Tip |
Targeting endoscopic healing (EH) is crucial, particularly in small bowel Crohn’s disease (CD), as EH is associated with better long-term outcomes. We have evaluated the usefulness of leucine-rich alpha-2 glycoprotein (LRG) as a biomarker in assessing EH and endoscopic activity in 133 consecutive patients with CD who underwent balloon-assisted enteroscopy. Our results indicate the usefulness of LRG in assessing EH and endoscopic activity in CD. Furthermore, the superiority of LRG over C-reactive protein has been demonstrated, especially in predicting EH in the small intestine. |
| Publish Date |
2025-02-13 02:41 |
| Citation |
Ohno M, Nishida A, Otsuki A, Yokota Y, Imai T, Bamba S, Inatomi O. Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease. World J Gastrointest Endosc 2025; 17(2): 100793
|
| URL |
https://www.wjgnet.com/1948-5190/full/v17/i2/100793.htm |
| DOI |
https://dx.doi.org/10.4253/wjge.v17.i2.100793 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
